ProQR Therapeutics (PRQR) EPS (Weighted Average and Diluted) (2014 - 2025)
ProQR Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.07 in Q4 2025, up 100.0% quarter-over-quarter from -$34465.6 in Q3 2025, and up 30.35% year-over-year from -$0.06 in Q4 2024.
ProQR Therapeutics' EPS (Weighted Average and Diluted) history runs 12 years deep, the most recent figure standing at -$0.07 for Q4 2025.
- In Q4 2025, EPS (Weighted Average and Diluted) rose 30.35% year-over-year to -$0.07; the TTM figure through Dec 2025 stood at -$0.07 (up 30.35% YoY), while the FY2025 annual figure was -$0.47, down 36.17% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.07 for Q4 2025 at ProQR Therapeutics, up from -$34465.6 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.06 in Q4 2023 to a low of -$104500.0 in Q1 2025.
- A 5-year average of -$37390.5 and a median of -$33781.8 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) sank 211.73% in 2021 and jumped 100.0% in 2022, its largest moves.
- ProQR Therapeutics' EPS (Weighted Average and Diluted) stood at -$18980.2 in 2021, then soared by 100.0% to -$0.19 in 2022, then surged by 67.17% to -$0.06 in 2023, then tumbled by 75.47% to -$0.11 in 2024, then surged by 30.35% to -$0.07 in 2025.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.07, -$34465.6, and -$61242.9 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -34,465.63 |
| Jun 30, 2025 | -61,242.86 |
| Mar 31, 2025 | -104,500.00 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -36,891.30 |
| Jun 30, 2024 | -20,707.69 |
| Mar 31, 2024 | -85,088.89 |
| Dec 31, 2023 | -0.06 |
| Sep 30, 2023 | -21,589.29 |
| Jun 30, 2023 | -38,061.90 |
| Mar 31, 2023 | -83,200.00 |
| Dec 31, 2022 | -0.19 |
| Sep 30, 2022 | -32,386.11 |
| Jun 30, 2022 | -35,128.21 |
| Mar 31, 2022 | -70,545.00 |
| Dec 31, 2021 | -18,980.21 |
| Sep 30, 2021 | -21,495.71 |
| Jun 30, 2021 | -33,097.92 |
| Mar 31, 2021 | -50,428.00 |
| Dec 31, 2020 | -14,433.33 |
| Sep 30, 2020 | -20,053.73 |
| Jun 30, 2020 | -10,617.50 |
| Mar 31, 2020 | -50,171.88 |
| Dec 31, 2019 | -13,430.43 |
| Sep 30, 2019 | -12,386.73 |
| Jun 30, 2019 | -17,653.03 |
| Mar 31, 2019 | -39,325.00 |
| Dec 31, 2018 | -11,875.23 |
| Sep 30, 2018 | -8,052.70 |
| Jun 30, 2018 | -12,880.70 |
| Mar 31, 2018 | 0.32 |
| Dec 31, 2017 | 6,559.88 |
| Sep 30, 2017 | 0.08 |
| Jun 30, 2017 | -12,351.09 |
| Mar 31, 2017 | 23,288.89 |
| Mar 31, 2016 | -0.38 |
| Mar 31, 2015 | -11.67 Mn |
| Mar 31, 2014 | -0.29 |